Engineered bacteria to accelerate wound healing: an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trial

BACKGROUND: Impaired wound healing is a growing medical problem and very few approved drugs with documented clinical efficacy are available. CXCL12-expressing lactic acid bacteria, Limosilactobacillus reuteri (ILP100-Topical), has been demonstrated to accelerate wound healing in controlled preclinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Öhnstedt, Emelie, Vågesjö, Evelina, Fasth, Andreas, Lofton Tomenius, Hava, Dahg, Pia, Jönsson, Sofia, Tyagi, Nisha, Åström, Mikael, Myktybekova, Zhanar, Ringstad, Lovisa, Jorvid, Margareth, Frank, Peter, Hedén, Per, Roos, Stefan, Phillipson, Mia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220316/
https://www.ncbi.nlm.nih.gov/pubmed/37251631
http://dx.doi.org/10.1016/j.eclinm.2023.102014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220316/
https://www.ncbi.nlm.nih.gov/pubmed/37251631
http://dx.doi.org/10.1016/j.eclinm.2023.102014

Ejemplares similares